Thromb Haemost 2012; 107(02): 315-327
DOI: 10.1160/TH11-07-0492
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Functional mapping of the A2 domain from human factor VIII

Jean-Luc Plantier
1   Laboratoire d’hémobiologie EA4174-IFR62 Faculté de médecine RTH Laennec, Université de Lyon, Lyon, France
,
Didier Saboulard
2   Biométhodes, Evry, France
,
Jean-Luc Pellequer
3   CEA, iBEB, Service de Biochimie et Toxicologie Nucléaire, Bagnols sur Cèze, France
,
Claude Négrier*
1   Laboratoire d’hémobiologie EA4174-IFR62 Faculté de médecine RTH Laennec, Université de Lyon, Lyon, France
,
Marc Delcourt*
2   Biométhodes, Evry, France
4   Present address: Global Bioenergies, Evry, France
› Author Affiliations
Further Information

Publication History

Received: 20 July 2011

Accepted after major revision: 24 January 2011

Publication Date:
29 November 2017 (online)

Summary

Coagulation factor VIII (FVIII) is a multidomain glycoprotein in which the FVIII A2 domain is a key structural element. We aimed at identifying residues within FVIII A2 domain that are crucial for the maintenance of the cofactor function. A high number (n=206) of mutants were generated by substituting original residues with alanine. The mutants were expressed in COS-1 cells and their antigen levels and procoagulant activities were measured. The residues were classified in three categories: those with a non-detrimental alteration of their activities (activity >50 % of control FVIII; n=98), those with a moderate alteration (15 %<activity<50%; n=45) and those that were severely affected (activity<15%; n=63). The mutants sensitive to mutation were retrieved in the HAMSTeRS database with a higher percentage than those that were not affected (58.8% vs. 9.2%). The results revealed the existence of clusters of residues that are sensitive (Arg418-Phe436, Thr459-Ile475, Ser535-Gly549, Asn618-Ala635) or not (Leu398-Arg418, Pro485-Asp500, Gly506-Gly520, Pro596-Asp605) to mutations. The stretches of residues sensitive to mutations were buried within the molecule suggesting that these amino acids participate in the maintenance of the A2 domain structure. In contrast, residues resistant to mutations formed external loops without well- defined structures suggesting that these loops were not crucial for the process of factor X activation. This study provided a detailed map of the FVIII A2 domain between residues 371 and 649, identifying residues crucial for maintaining FVIII function and residues that can be mutated without jeopardising the coagulant activity.

* Both authors contributed equally to the work.


 
  • References

  • 1 Toole JJ, Knopf JL, Wozney JM. et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-347.
  • 2 Vehar GA, Keyt B, Eaton D. et al. Structure of human factor VIII. Nature 1984; 312: 337-342.
  • 3 Eaton D, Rodriguez H, Vehar GA.. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512.
  • 4 Pittman DD, Kaufman RJ.. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci USA 1988; 85: 2429-2433.
  • 5 Fay PJ, Haidaris PJ, Smudzin TM.. Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 1991; 266: 8957-8962.
  • 6 Lollar P, Parker ET, Fay PJ.. Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem 1992; 267: 23652-23657.
  • 7 Duncan EM, Duncan BM, Tunbridge LJ. et al. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 1994; 87: 846-848.
  • 8 Pipe SW, Eickhorst AN, McKinley SH. et al. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 1999; 93: 176-183.
  • 9 Parker ET, Lollar P.. Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation. Biochemistry 2007; 46: 9737-9742.
  • 10 Wakabayashi H, Fay PJ.. Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa. J Biol Chem 2008; 283: 11645-11651.
  • 11 Gale AJ, Pellequer JL.. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa.. J Thromb Haemost 2003; 1: 1966-1971.
  • 12 Gale AJ, Radtke KP, Cunningham MA. et al JH. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.. J Thromb Haemost 2006; 4: 1315-1322.
  • 13 Fay PJ, Beattie T, Huggins CF. et al. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 1994; 269: 20522-20527.
  • 14 Fay PJ, Scandella D.. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999; 274: 29826-29830.
  • 15 Bovenschen N, van Stempvoort G, Voorberg J. et al. Proteolytic cleavage of factor VIII heavy chain is required to expose the binding-site for low-density lipoprotein receptor-related protein within the A2 domain.. J Thromb Haemost 2006; 4: 1487-1493.
  • 16 Sarafanov AG, Ananyeva NM, Shima M. et al. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein.. J Biol Chem 2001; 276: 11970-11979.
  • 17 Sarafanov AG, Makogonenko EM, Pechik IV. et al. Identification of coagulation factor VIII A2 domain residues forming the binding epitope for low-density lipoprotein receptor-related protein.. Biochemistry 2006; 45: 1829-1840.
  • 18 Plantier JL, Rolli V, Ducasse C. et al. Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency.. J Thromb Haemost 2010; 8: 286-293.
  • 19 Healey JF, Parker ET, Barrow RT. et al. The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice.. Thromb Haemost 2009; 102: 35-41.
  • 20 Scandella D, Mattingly M, de Graaf S. et al. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-1626.
  • 21 Pellequer JL, Chen SW, Saboulard D. et al. Functional mapping of factor VIII C2 domain.. Thromb Haemost 2011; 106: 121-131.
  • 22 Saboulard D, Dugas V, Jaber M. et al. High-throughput site-directed mutagenesis using oligonucleotides synthesized on DNA chips.. Biotechniques 2005; 39: 363-368.
  • 23 Ngo JC, Huang M, Roth DA. et al. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.. Structure 2008; 16: 597-606.
  • 24 Kraulis PJ.. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structure. Journal of Applied Crystallography 1991; 24: 946-950.
  • 25 Merritt EA, Bacon DJ.. Raster3D: photorealistic molecular graphics. Methods Enzymol 1997; 277: 505-524.
  • 26 Amano K, Sarkar R, Pemberton S. et al. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. Blood 1998; 91: 538-548.
  • 27 Jenkins PV, Freas J, Schmidt KM. et al. Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex.. Blood 2002; 100: 501-508.
  • 28 Jagannathan I, Ichikawa HT, Kruger T. et al. Identification of residues in the 558-loop of factor VIIIa A2 subunit that interact with factor IXa.. J Biol Chem 2009; 284: 32248-32255.
  • 29 Nogami K, Saenko EL, Takeyama M. et al. Identification of a thrombin-interactive site within the FVIII A2 domain that is responsible for the cleavage at Arg372.. Br J Haematol 2008; 140: 433-443.
  • 30 Roelse JC, De Laaf RT, Timmermans SM. et al. Intracellular accumulation of factor VIII induced by missense mutations Arg593-->Cys and Asn618-->Ser explains cross-reacting material-reduced haemophilia A.. Br J Haematol 2000; 108: 241-246.
  • 31 Marquette KA, Pittman DD, Kaufman RJ.. A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells. J Biol Chem 1995; 270: 10297-10303.
  • 32 Mertens K, van Wijngaarden A, Bertina RM. et al. The functional defect of factor VIII Leiden, a genetic variant of coagulation factor VIII. Thromb Haemost 1985; 54: 650-653.
  • 33 Jenkins PV, Dill JL, Zhou Q. et al. Clustered basic residues within segment 484-510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation.. J Thromb Haemost 2004; 2: 452-458.
  • 34 Nogami K, Zhou Q, Myles T. et al. Exosite-interactive regions in the A1 and A2 domains of factor VIII facilitate thrombin-catalyzed cleavage of heavy chain.. J Biol Chem 2005; 280: 18476-18487.
  • 35 O'Brien LM, Medved LV, Fay PJ.. Localization of factor IXa and factor VIIIa interactive sites. J Biol Chem 1995; 270: 27087-27092.
  • 36 Ananyeva NM, Makogonenko YM, Sarafanov AG. et al. Interaction of coagulation factor VIII with members of the low-density lipoprotein receptor family follows common mechanism and involves consensus residues within the A2 binding site 484-509.. Blood Coagul Fibrinolysis 2008; 19: 543-555.
  • 37 Takeyama M, Nogami K, Saenko EL. et al. Identification of a protein S-interactive site within the A2 domain of the factor VIII heavy chain. Thromb Haemost 2009; 102: 645-655.